Bryan Garnier - Oncimmune Holdings (ONC) ONCIMMUNE: Financial results in-line new strategy introduced | Corporate | 130p

Report

Bryan Garnier

Gary Waanders

ONCIMMUNE: Financial results in-line & new strategy introduced | Corporate | 130p

ONCIMMUNE - Corporate | 130p
Financial results in-line & new strategy introduced

Financial results for 12 months to May 31st 2018
Product development capabilities
New strategies
Valuation

31/10/2018 3 EN

Underlying

Oncimmune Holdings

Oncimmune Holdings and its subsidiaries are engaged in cancer diagnosis.

See profile

GB00BYQ94H38 London Stock Exchange United Kingdom

Provider

Bryan Garnier

Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.

See profile

Analysts

Gary Waanders

Other Reports on these Companies

Hybridan

Hybridan Small Cap Feast - 29 Feb 24

29th February 2024 @HybridanLLP Status of this Note and Disclaimer This document has been issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific entity and is not a personal recommendation to...

February 29, 2024 February 29, 2024 1 EN

Hybridan

Hybridan Small Cap Feast - 12 Jul 23

12th July 2023 @HybridanLLP Status of this Note and Disclaimer This document has been issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific entity and is not a personal recommendation to any...

July 12, 2023 July 12, 2023 1 EN

Hybridan

Hybridan Small Cap Feast - 22 May 23

22nd May 2023 @HybridanLLP Status of this Note and Disclaimer This document has been issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific entity and is not a personal recommendation to anyo...

May 22, 2023 May 22, 2023 1 EN

NHOA: Slow start into 2024

NHOA reported Q1 revenue of EUR58m (+57% YoY, -26% QoQ), a rather low quarter compared to FY24 revenue expectations (cons. at EUR430m), but with NHOA exposed to the overall pace of project deliveries in Energy Storage that can vary significantly quarter on quarter. Revenue mix did not improve this

15h / 45m 15h / 45m 1 EN

Maria Vara

Maria Vara

XVIVO: delivering a solid Q1 2024 performance

XVIVO reported Q1 2024 results with a YoY organic growth of 32% (32% adj. for currency) in net sales raising to SEK 186m. The solid performance was driven by i) thoracic business reporting a 33% YoY growth, totalling SEK 121m sales, with disposables sales rising by 39% as of larger utilization in t

15h / 51m 15h / 51m 1 EN

Cedric Rossi

Cedric Rossi

BIC: Soft Q1 followed by a gradual acceleration from Q2 onwards

Yesterday, BIC unveiled Q1 numbers that reflected management's message highlighting a soft start to the year, but showed a modest miss vs CSS expectations (sales: -1% / aEBIT: -1.5%) given the negative phasing impact in Lighters (38% of sales and 69% of aEBIT before unallocated costs). With trends

16h / 9m 16h / 9m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

ONCIMMUNE: Financial results in-line & new strategy introduced | Corporate | 130p

Hybridan Small Cap Feast - 29 Feb 24

Hybridan Small Cap Feast - 12 Jul 23

Hybridan Small Cap Feast - 22 May 23

NHOA: Slow start into 2024

XVIVO: delivering a solid Q1 2024 performance

BIC: Soft Q1 followed by a gradual acceleration from Q2 onwards

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe